UNIVERSITY OF NORTH CAROLINA HOSPITALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1989-01-01

Employees: -

Market Cap: -

Website: http://www.unc.edu/interactive-tour/unc-hospitals/

Clinical Trials

Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors

Not Applicable

Completed

Conditions: Cognitive Impairment
Cancer, Breast

Interventions: Behavioral: Tai Chi

First Posted Date: 2017-06-22

Last Posted Date: 2019-03-07

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT03196037

Locations: 🇺🇸
UNC Chapel Hill Program on Integrative Medicine, Chapel Hill, North Carolina, United States

Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer

Withdrawn

Conditions: Metastatic Breast Cancer

First Posted Date: 2017-05-22

Last Posted Date: 2021-05-21

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Registration Number: NCT03161834

Locations: 🇺🇸
University of North Carolina at Chapel Hill Cancer Hospital, Chapel Hill, North Carolina, United States

HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi

Completed

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2017-05-19

Last Posted Date: 2023-01-06

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 600

Registration Number: NCT03160209

Locations: 🇲🇼
UNC Project, Lilongwe, Malawi
🇲🇼
UNC Project, Lighthouse Trust, Lilongwe, Malawi

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

Phase 2

Completed

Conditions: Melanoma

Interventions: Diagnostic Test: FDG PET/CT scan
Diagnostic Test: C11-AMT PET scan
Drug: Pembrolizumab
Diagnostic Test: CT scan

First Posted Date: 2017-03-24

Last Posted Date: 2023-11-15

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 27

Registration Number: NCT03089606

Locations: 🇺🇸
UNC Rex Healthcare, Raleigh, North Carolina, United States
🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell
Head and Neck Neoplasms
Oropharyngeal Neoplasms

Interventions: Radiation: Intensity Modulated Radiotherapy (IMRT)
Drug: Cisplatin (or alternative)
Procedure: Assessment for surgical evaluation

First Posted Date: 2017-03-10

Last Posted Date: 2024-05-02

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 195

Registration Number: NCT03077243

Locations: 🇺🇸
University of Florida Proton Therapy Institute, Jacksonville, Florida, United States
🇺🇸
Rex Healthcare, Raleigh, North Carolina, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

and more 1 locations

Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation

Completed

Conditions: Malignant Solid Tumor
Hematologic Malignancies

Interventions: Device: Biometric Devices
Other: Physical Performance Testing

First Posted Date: 2016-07-26

Last Posted Date: 2019-02-22

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 67

Registration Number: NCT02844400

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Pembrolizumab
Drug: Cyclophosphamide

First Posted Date: 2016-05-11

Last Posted Date: 2023-05-22

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT02768701

Locations: 🇺🇸
George Washington University-Medical Faculty Associates, Washington, District of Columbia, United States
🇺🇸
Rex Cancer Center, Raleigh, North Carolina, United States
🇺🇸
Cone Health Cancer Center, Greensboro, North Carolina, United States

and more 2 locations

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

Early Phase 1

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Atorvastatin

First Posted Date: 2016-05-10

Last Posted Date: 2020-07-07

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT02767362

Locations: 🇺🇸
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

Phase 1

Terminated

Conditions: Diffuse Large B-cell Lymphoma
Follicular Lymphoma
Burkitt Lymphoma

Interventions: Drug: Alisertib

First Posted Date: 2016-03-07

Last Posted Date: 2017-11-20

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT02700022

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hills, North Carolina, United States

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: pembrolizumab, gemcitabine and cisplatin

First Posted Date: 2016-02-24

Last Posted Date: 2024-02-07

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 39

Registration Number: NCT02690558

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
North Carolina Cancer Hospital (UNC), Chapel Hill, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy